• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Julie Maréchal-Jamil: Challenges for Biosimilars in Europe

Video

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the challenges ahead for the European biosimilars market.

Transcript:

If I look at the market unfolding, let's say, I think one of the very important notions that needs to be reconciled is the short-term policy regarding budget management and the longer-term goal of healthcare equity and a greater quality of care because you can't forget that end goal and compromise it; you need to make sure you have thoughtful policies in place today so that you're not compromising meeting the big end goal.

I think this is essential and it has to do with a general education that competition in the pharmaceutical market is a dynamic and cyclic system, and for that, the time element is really important. It has to be seen in a bigger time frame than just the cycle of a call for tender or a purchasing bid, or this type of element.

For us, the challenge this year will be to make sure everybody in the healthcare community, from the makers to the end users, do have that time element to it. Yes there is “what's in it for me?” at every bit, but I think the time element will condition how deliverables are are actually happening or not, so this is really important.

Related Videos
Jeffrey Casberg, RPh, MS.
Adam Colborn, JD.
Legal scale weighs profit as greater than medical treatment
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Brian Biehn
Chelsee Jensen, PharmD, BCPS
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2024 MJH Life Sciences

All rights reserved.